XML 95 R84.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue from Contracts with Customers (Narrative) (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
May 17, 2021
USD ($)
Dec. 20, 2018
Option
Sep. 20, 2018
Feb. 14, 2017
Nov. 30, 2015
Program
Feb. 19, 2015
USD ($)
Program
Jan. 09, 2015
USD ($)
Program
Dec. 31, 2023
USD ($)
Oct. 31, 2021
USD ($)
Jul. 31, 2021
USD ($)
Jul. 31, 2020
USD ($)
Nov. 30, 2019
USD ($)
Mar. 31, 2012
USD ($)
Jul. 31, 2007
USD ($)
Jul. 31, 2006
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2017
USD ($)
Revenue From Contract With Customer [Line Items]                                        
Revenue                                 $ 103,463,000 $ 156,314,000 $ 98,024,000  
Shares sold at the market                                 33,023,000 133,157,000 99,211,000  
Contract with customer, liability, revenue recognized                                 14,000      
Asset impairment charges                                 1,973,000   6,111,000  
Capitalized contract , cost                                 0      
Contract Assets [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Asset impairment charges                                 0      
GSK Supply Agreement [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Milestone payments for license costs                             $ 5,000,000          
Additional fixed fee for license costs                           $ 7,300,000            
Negotiation right expiry date                         2017-03              
Proceeds from negotiation right                         $ 9,000,000              
Proceeds from negotiation right creditable against future royalty payments                         $ 2,500,000              
UroGen License Agreement [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Proceeds from collaborators                       $ 10,000,000.0                
Revenue                                 300,000 100,000 200,000  
GSK Agreements [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Royalty payments on net sales (as a percent)                         2.00%              
Total potential proceeds from license                                       $ 24,300,000
Period to receive license fees                         10 years              
Milestone method revenue recognized                                     25,300,000  
Non-cash royalty revenue recognized                                 101,000,000 114,600,000 45,300,000  
Incyte Corporation [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Revenue                                 0      
Number of collaboration agreement programs | Program           4                            
Discovery period of antibodies development and commercialization period           5 years                            
Extended discovery period of antibodies development and commercialization period           3 years                            
Incyte Corporation [Member] | Agenus Inc [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Number of collaboration agreement programs | Program         3                              
License Agreement [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Proceeds from collaborators                   $ 200,000,000                    
Betta Pharmaceuticals Collaboration Agreement [Member] | Betta Pharmaceuticals Co., Ltd [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Upfront payment received                     $ 15,000,000                  
Betta Pharmaceuticals Collaboration Agreement [Member] | Betta Pharmaceuticals Co., Ltd [Member] | Fixed Consideration [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Upfront payment received                     15,000,000                  
Collaborative Arrangement [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Percentage of profit and costs sharing ratio             50.00%                          
Collaborative Arrangement [Member] | Gilead Sciences, Inc. [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Transaction price recognized                                     9,500,000  
Revenue                                 0      
Collaborative Arrangement [Member] | Incyte Corporation [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Proceeds from collaborators             $ 25,000,000                          
Royalty payments on net sales (as a percent)       15.00%                                
Proceeds from milestones recognized                               $ 5,000,000.0        
Upfront payment received related to clinical development           $ 20,000,000                            
Option And License Agreements [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Number of separate option and license agreements | Option   2                                    
Royalty Purchase Agreement [Member] | Incyte Corporation [Member] | XOMA [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Percentage of sold future royalties right to receive     33.00%                                  
Percentage of sold future milestones right to receive     10.00%                                  
Maximum [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Royalty payments on net sales (as a percent)             12.00%                          
Maximum [Member] | UroGen License Agreement [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Royalty payments on net sales (as a percent)                       20.00%                
Maximum [Member] | Betta Pharmaceuticals Collaboration Agreement [Member] | Betta Pharmaceuticals Co., Ltd [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Aggregate potential milestones receivable                     $ 100,000,000                  
Minimum [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Royalty payments on net sales (as a percent)             6.00%                          
Minimum [Member] | UroGen License Agreement [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Royalty payments on net sales (as a percent)                       14.00%                
Development Regulatory And Commercialization Milestones [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Reserved right to elect to co-fund of development costs (as a percent)             30.00%                          
Development Regulatory And Commercialization Milestones [Member] | Maximum [Member] | UroGen License Agreement [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Potential milestone payments receivable                       $ 200,000,000.0                
Bristol Myers Squibb Company License Agreement [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Fee received $ 200,000,000                 $ 200,000,000                    
Aggregate potential milestones receivable               $ 25,000,000 $ 20,000,000                      
Bristol Myers Squibb Company License Agreement [Member] | Development Regulatory And Commercialization Milestones [Member] | Maximum [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Potential milestone payments receivable $ 1,360,000,000                                      
Upfront License Fee [Member] | GSK Supply Agreement [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Proceeds from collaborators                             $ 3,000,000          
Upfront License Fee [Member] | UroGen License Agreement [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Fee received                       $ 10,000,000                
Profit-share Products [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Number of collaboration agreement programs | Program             2                          
Milestone payments for license costs             $ 20,000,000                          
Royalty-bearing Products [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Number of collaboration agreement programs | Program             1                          
Milestone payments for license costs             $ 155,000,000                          
Research and Development Revenue [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Revenue                                 482,000 38,764,000 16,975,000  
Research and Development Revenue [Member] | Incyte Corporation [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Revenue                                   1,400,000 1,600,000  
Research and Development Revenue [Member] | License Agreement [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Aggregate potential milestones receivable                                   25,000,000    
Revenue                                 0   0  
Research and Development Revenue [Member] | Betta Pharmaceuticals Collaboration Agreement [Member] | Betta Pharmaceuticals Co., Ltd [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Revenue                                 $ 0 700,000    
Research and Development Revenue [Member] | Collaborative Arrangement [Member] | Gilead Sciences, Inc. [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Revenue                                   12,200,000 5,000,000  
Research and development services [Member]                                        
Revenue From Contract With Customer [Line Items]                                        
Revenue                                   $ 1,435,000 $ 1,676,000